Captrust Financial Advisors Aurinia Pharmaceuticals Inc. Transaction History

Captrust Financial Advisors

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 16, 2022	SELL	$8.95 - $12.8 $4,475 - $6,400	-500 Reduced 22.73%	1,700 $17,000
Q2 2021 Aug 16, 2021	SELL	$10.0 - $14.52 $20,000 - $29,040	-2,000 Reduced 47.62%	2,200 $29,000
Q1 2021 May 17, 2021	BUY	$12.3 - $18.73 $24,600 - $37,460	2,000 Added 90.91%	4,200 $55,000
Q2 2020 Aug 14, 2020	BUY	$14.12 - $18.33 $31,064 - $40,325	2,200 New	2,200 $35,000
Q4 2019 Feb 14, 2020	SELL	$3.88 - $21.42 $8,536 - $47,124	-2,200 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$6.06 - $7.64 $13,332 - $16,808	2,200 New	2,200 $14,000

208

58.1M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.14B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.